Dilution of Share Value from Exercise of Stock Options
First written in FY2019. 10 of 19 entries say "Materialised", first in FY2020. Latest entry: FY2026.
Ips moved to the "Worse" side of this theme in 2019, 1 year before the typical company in this theme (2020).
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
53 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「As of 31 March 2026, the number of potential shares represented by these stock options was 532,100, equivalent to 4.07% of total issued shares of 13,082,400.」
The number of potential shares declined from 686,200 in the previous fiscal year to 532,100, while the ratio to total shares outstanding fell from 5.29% to 4.07%. Meanwhile, 119,100 shares were issued during the current fiscal year upon the exercise of stock acquisition rights. - FY2026-H1MaterialisedAnnual report
「1 April 2025–30 September 2025 52,400 13,015,700 43 1,251 43 1,191 (Note) 1. Increase resulting from the exercise of stock acquisition rights.」
During the six-month consolidated accounting period, total issued shares increased by 52,400 as a result of the exercise of stock acquisition rights. A further increase of 47,500 shares in October 2025 was also disclosed. - FY2025Updated potential-share ratioAnnual report
「As of 31 March 2025, the number of potential shares represented by these stock options was 686,200, equivalent to 5.29% of total issued shares of 12,963,300.」
The number of potential shares from stock options was disclosed as 686,200, representing 5.29% of total issued shares. Although 95,500 shares were added through the exercise of stock acquisition rights during the fiscal year, a further 200,000 potential shares granted in July 2024 were also included. - FY2025-H1WorsenedAnnual report
「Class, details and number of shares underlying the stock acquisition rights (shares)* Common shares: 110,000 (Note) 1 Class, details and number of shares underlying the stock acquisition rights (shares)* Common shares: 90,000 (Note) 1」
For the stock acquisition rights issued on 22 July 2024, a new grant representing a total of 200,000 potential shares was disclosed. In addition, from April to September 2024, the number of issued shares increased by 42,600 through the exercise of stock acquisition rights, expanding and materializing the dilution factor. - FY2024-Q3MaterialisedAnnual report
「1 October 2023–31 December 2023 407,800 12,857,200 20 1,136 20 1,076 (Note) Increase resulting from the exercise of stock acquisition rights.」
During the third-quarter accounting period, total issued shares increased by 407,800 as a result of the exercise of stock acquisition rights, and the dilution factor from stock options materialized significantly. - FY2024-Q2MaterialisedAnnual report
「1 July 2023–30 September 2023 8,600 12,449,400 7 1,116 7 1,056 (Note) 1. Increase resulting from the exercise of stock acquisition rights.」
During the second-quarter accounting period, total issued shares increased by 8,600 as a result of the exercise of stock acquisition rights, and the dilution factor from stock options materialized in practice. - FY2024-Q1MaterialisedAnnual report
「From 1 July 2023 to 31 July 2023, total issued shares increased by 6 thousand as a result of the exercise of stock acquisition rights, while capital and capital reserves each increased by ¥4 million.」
Following the end of the quarter, total issued shares increased by 6 thousand through the exercise of stock acquisition rights, and the dilution factor from stock options continued to materialize in practice. - FY2023-Q3MaterialisedAnnual report
「1 October 2022–31 December 2022 2,700 12,437,200 2 1,106 2 1,046 (Note) Increase resulting from the exercise of stock acquisition rights.」
During the third-quarter accounting period, 2,700 shares were added through the exercise of stock acquisition rights, and the dilution factor from stock options continued to materialize in practice. - FY2023-Q2MaterialisedAnnual report
「1 July 2022–30 September 2022 24,000 12,434,500 19 1,104 19 1,044 (Note) Increase resulting from the exercise of stock acquisition rights.」
During the second-quarter accounting period, the number of issued shares increased by 24,000 as a result of the exercise of stock acquisition rights, and the dilution factor materialized in practice. - FY2023-Q1WorsenedAnnual report
「Number of stock acquisition rights (units)* 400 (Note) 2 Class, details and number of shares underlying the stock acquisition rights (shares)* Common shares: 40,000 shares (Note) 2 Exercise period for the stock acquisition rights* From 14 April 2025 to 13 April 2032」
Based on the resolution of 13 April 2022, stock acquisition rights representing 40,000 common shares were issued to 3 employees of the company. An additional potential source of dilution in share value was created. - FY2022WorsenedAnnual report
「As of 31 March 2022, the number of potential shares represented by these stock options was 829,750, excluding vested but unexercised stock acquisition rights under the incentive plan using the trust described above, equivalent to 6.7% of total issued shares of 12,410,500.」
The number of potential shares was disclosed as 829,750, representing 6.7% of total issued shares, quantitatively disclosing the potential dilution from the exercise of stock options. - FY2022-Q3MaterialisedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
From October to December 2021, total issued shares increased by 7,000 as a result of the exercise of stock acquisition rights, and the dilution factor continued to materialize. - FY2022-Q2MaterialisedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
During the second-quarter accounting period, total issued shares increased by 17,000 as a result of the exercise of stock acquisition rights, and the dilution factor continued to materialize in practice. - FY2021-Q1MaterialisedAnnual report
「The increase resulted from the exercise of share acquisition rights.」
During the first-quarter accounting period, total issued shares increased by 20,000 as a result of the exercise of stock acquisition rights, and the dilution factor continued to materialize. - FY2020MaterialisedAnnual report
「Increase resulting from the exercise of stock acquisition rights (stock options): 150,000 shares」
During the consolidated fiscal year, 150,000 shares were added through the exercise of stock options. The number of potential shares from ordinary stock options at the end of the fiscal year was disclosed as 480,000, excluding the trust-based incentive plan. - FY2020-Q3WorsenedAnnual report
「1 October 2019–31 December 2019 24,000 12,350,000 1,960 1,064,692 1,960 1,004,792 (Note) Increase resulting from the exercise of stock acquisition rights (stock options).」
During the third-quarter accounting period, the number of shares increased by 24,000 as a result of the exercise of stock acquisition rights, bringing total issued shares to 12,350,000. The dilution factor from previously disclosed stock acquisition rights continued to materialize. - FY2020-Q2WorsenedAnnual report
「Increase resulting from the exercise of stock acquisition rights (stock options).」
During the cumulative second-quarter period, the number of issued shares increased by 76,000 as a result of the exercise of stock acquisition rights. In addition, 612,500 shares were issued under the seventh series of stock acquisition rights, making the potential dilution factor more concrete. - FY2020-Q1WorsenedAnnual report
「Increase resulting from the exercise of stock acquisition rights (stock options)." "Number of potential shares from the issuance: 612,500 shares」
The number of issued shares increased by 50,000 from April to June 2019 as a result of the exercise of stock acquisition rights. In addition, as a subsequent event, a resolution was passed to issue 612,500 potential shares under the seventh series of stock acquisition rights, newly disclosing the potential scale of dilution. - FY2019First statedAnnual report
「As of the date of filing this document, the number of potential shares represented by these stock options was 580,000, equivalent to 4.7% of the total 12,250,000 issued shares.」
The potential dilution risk from the issuance of new shares upon exercise of stock options, including the dilution of per-share equity value and voting rights, was quantified as 580,000 potential shares, or 4.7% of total issued shares.